17 reports

  • INHERENT CHALLENGES WITH OLIGONUCLEOTIDE THERAPIES
  • ANTISENSE/RNAI OLIGONUCLEOTIDES - MARKET SIZE AND FORECAST 2017-2022

About Oligonucleotide Therapeutics Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases. Technavio’s analysts forecast...

  • Oligonucleotide
  • Therapy
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.

Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthesis Service Type Segment to Hold ##% Market Share by 2025 ##.

  • Genomics
  • Oligonucleotide
  • World
  • Market Size

Oligonucleotide Synthesis Market ##.

  • Genomics
  • Oligonucleotide
  • APAC
  • World
  • Forecast

Oligonucleotide Synthesis Market by Offering, by Application, by End User, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023 Chapter ##.

  • Genomics
  • Oligonucleotide
  • Europe
  • North America
  • World

Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By End Use, By Product, By Application And Segment Forecasts, 2018 - 2025 Chapter ## Executive Summary ##. ## Market Snapshot Chapter ## Research Methodology ##. ## Information procurement ##. ##. ## Purchased database: ##

  • Genomics
  • Oligonucleotide
  • United States
  • Demand
  • Forecast

Global Oligonucleotide Synthesis Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Product, by Application, by End User Chapter ##.

  • Genomics
  • Oligonucleotide
  • World
  • Forecast
  • DNA OLIGONUCLEOTIDES
  • OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%. The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech...

  • Oligonucleotide
  • North America
  • United States
  • Forecast
  • Merck & Co., Inc.
  • GLOBAL OLIGONUCLEOTIDE POOL MARKET SHARE, BY APPLICATIONS, 2016 (%)
  • GLOBAL OLIGONUCLEOTIDE POOL MARKET BY REGION, 2016 (%)

The Global Oligonucleotide pool market was valued at $ 1,292.8 million in 2016 and expected to reach at $2,324 million by 2022 at a CAGR of 8.5% during the forecast period. The major factors responsible for the growth of global Oligonucleotide pool market are big pharmaceutical companies investing in oligonucleotide therapeutics for drug...

  • Oligonucleotide
  • United States
  • World
  • Forecast
  • Agilent Technologies, Inc.
  • OLIGONUCLEOTIDES SEGMENT TO COMMAND THE LARGEST SHARE IN THE
  • SYNTHETIC BIOLOGY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2015-2022 (USD MILLION)

The global synthetic biology market is projected to grow at a CAGR of 19.9%. in the next five years The synthetic biology market is expected to reach USD 8.84 billion by 2022 from an estimated USD 3.57 billion in 2017, at a CAGR of 19.9%. The key factors driving the growth of this market include the wide range of applications...

  • Oligonucleotide
  • North America
  • United States
  • Market Size
  • Thermo Fisher Scientific, Inc.
  • NOV 29, 2017: AJINOMOTO TO ESTABLISH A NEW DEVELOPMENT AND PRODUCTION BASE FOR OLIGONUCLEOTIDE DRUG SUBSTANCES

Summary Ajinomoto Co Inc (Ajinomoto) is a food products company that focuses on foods, bioscience fine chemicals and pharmaceuticals and health.It carries out research and development and production of seasonings, and provides Knorr cup soup products, processed foods, edible oils, sweeteners, beverages, amino acids, pharmaceuticals...

  • Oligonucleotide
  • Japan
  • United States
  • M&A
  • Ajinomoto Co., Inc.
  • ANTISENSE OLIGONUCLEOTIDE TO ACTIVATE DYSTROPHIN FOR DUCHENNE MUSCULAR DYSTROPHY - DRUG PROFILE
  • ANTISENSE OLIGONUCLEOTIDE TO ACTIVATE DYSTROPHIN FOR DUCHENNE MUSCULAR DYSTROPHY - DRUG PROFILE

Dystrophin (DMD) - Pipeline Review, H2 2017 Summary According to the recently published report ’Dystrophin (DMD) - Pipeline Review, H2 2017’; Dystrophin (DMD) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the...

  • Gene Therapy
  • Neurological Disorder
  • Oligonucleotide
  • Therapy
  • Sarepta Therapeutics, Inc.
  • ANTISENSE OLIGONUCLEOTIDE 2 TO INHIBIT HUNTINGTIN PROTEIN FOR HUNTINGTON'S DISEASE - DRUG PROFILE
  • ANTISENSE OLIGONUCLEOTIDE 1 TO INHIBIT HUNTINGTIN PROTEIN FOR HUNTINGTON'S DISEASE - DRUG PROFILE

Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein) targeted pipeline therapeutics. The report provides comprehensive information...

  • Dementia
  • Oligonucleotide
  • Therapy
  • United States
  • Product Initiative
  • OLIGONUCLEOTIDE FOR HIV
  • OLIGONUCLEOTIDE FOR CANCER

CureVac GmbH - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘CureVac GmbH - Product Pipeline Review - 2016’, provides an overview of the CureVac GmbH’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CureVac...

  • Oligonucleotide
  • Vaccine
  • United States
  • Company Operations
  • CureVac GmbH
  • DEAL RATIONALE
  • 05/01/2017: PROQR TO PRESENT DATA ON QRX-411 AT ARVO

Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders.The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat...

  • Oligonucleotide
  • Pharmaceutical
  • Therapy
  • United States
  • ProQR Therapeutics N.V.
  • OLIGONUCLEOTIDE FOR NEUROINFLAMMATION
  • ANTISENSE OLIGONUCLEOTIDE TO ACTIVATE DYSTROPHIN FOR DUCHENE MUSCULAR DYSTROPHY

nLife Therapeutics, S.L. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘nLife Therapeutics, S.L. - Product Pipeline Review - 2015’, provides an overview of the nLife Therapeutics, S.L.’s pharmaceutical research and development focus. This report provides comprehensive information on the current...

  • Oligonucleotide
  • Research And Development
  • Therapy
  • World
  • Company Operations

Antisense oligonucleotide inhibits the expression of NDM-##.

  • Oligonucleotide
  • Therapy
  • United States
  • Company Operations
  • Sarepta Therapeutics, Inc.
  • Biosearch Technologies targets and partners (2012 -YTD2016)

Partner ##: QIAGEN N. V.

  • Genomics
  • Oligonucleotide
  • United States
  • M&A
  • Biosearch Technologies, Inc.